| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/14/2023 | 226.09% | Cantor Fitzgerald | → $3 | Reiterates | Overweight → Overweight |
| 05/19/2023 | 552.17% | Canaccord Genuity | $5 → $6 | Maintains | Buy |
| 12/17/2021 | 769.57% | Cantor Fitzgerald | → $8 | Initiates Coverage On | → Overweight |
| 12/03/2021 | 769.57% | Canaccord Genuity | → $8 | Initiates Coverage On | → Buy |
What is the target price for Cardiol Therapeutics (CRDL)?
The latest price target for Cardiol Therapeutics (NASDAQ: CRDL) was reported by Cantor Fitzgerald on August 14, 2023. The analyst firm set a price target for $3.00 expecting CRDL to rise to within 12 months (a possible 226.09% upside). 2 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cardiol Therapeutics (CRDL)?
The latest analyst rating for Cardiol Therapeutics (NASDAQ: CRDL) was provided by Cantor Fitzgerald, and Cardiol Therapeutics reiterated their overweight rating.
When is the next analyst rating going to be posted or updated for Cardiol Therapeutics (CRDL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cardiol Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cardiol Therapeutics was filed on August 14, 2023 so you should expect the next rating to be made available sometime around August 14, 2024.
Is the Analyst Rating Cardiol Therapeutics (CRDL) correct?
While ratings are subjective and will change, the latest Cardiol Therapeutics (CRDL) rating was a reiterated with a price target of $0.00 to $3.00. The current price Cardiol Therapeutics (CRDL) is trading at is $0.92, which is within the analyst's predicted range.